ICON plc has launched ICONIK Patient Safety, its latest service leveraging its ICONIK technology platform. According to the company, it offers a systematic way to monitor safety trends in accumulating data, spot potential safety issues and take appropriate corrective and preventative action while the study is on going. Data can be queried at any level of detail (single patient, single site, across an entire study or entire compound), and aims to help sponsors make informed, data driven decisions.
Dr. Peter Schueler, senior vice president Medical & Safety Services, ICON Clinical Research, said, “Patient well-being is paramount in any clinical trial. ICONIK Patient Safety allows real-time review of integrated patient safety data, thereby improving our ability to identify and monitor unexpected adverse events. ICONIK Patient Safety helps study teams maintain a view of a drug’s evolving safety profile by accumulating safety data in real-time and allowing for quick identification of emerging safety issues, affording greater protection of patients’ well-being. Before ICONIK Patient Safety, this level of dynamic analysis and management of patient safety was simply not possible.”